Japanese launch for once-daily tacrolimus
This article was originally published in Scrip
Executive Summary
Astellaswill launch Graceptor, its once-daily formulation of the immunosuppressant tacrolimus, in Japan on October 28th. The oral product is indicated for organ rejection in kidney, liver, heart, lung and pancreas transplants, and graft rejection and graft-versus-host disease in bone marrow transplantation. It is already marketed (as Advagraf) in 19 other countries but has faced regulatory difficulties in the US, where the patent for Prograf, the standard release product, expired in April. Japanese pricing authorities predict peak annual reimbursement level sales of Graceptor will reach around ¥16 billion ($171.6 million).
You may also be interested in...
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: another big deal in radiopharmaceuticals; BioNTech’s ADC pipeline; China CDMOs embrace uncertain future; at look at the rivals in MASH; and industry views on how AI might be transformative.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Galderma prepares to take on Dupixent; Pfizer’s plans for Adcetris in DLBCL; Lilly’s donanemab approval delayed again; the psychedelic R&D pipeline; and an interview with BMS’s CDTO Greg Meyers.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Bayer won’t split, for now; Pfizer’s next-gen ADC pipeline; oncology dominates investment but other areas grow; goodbye NASH, hello MASH; and BMS’s CEO gives his views on India.